 |
|
| Blog results | Results 1 - 10 of about 1,661 for raloxifene trials. (0.46 seconds) |
| Sorted by relevance Sort by date |
| 17 Nov 2009 Analysis indicated that all three drugs reduced risk for invasive breast cancer compared with placebo: tamoxifen (risk ratio, 0.70; 95% CI, 0.59 to 0.82; 4 trials), raloxifene (risk ratio, 0.44; 95% CI, 0.27 to 0.71; 2 trials), ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 16 Nov 2009 by salud equitativa Based on limited data from head-to-head trials, superiority for the prevention of vertebral fractures has not been demonstrated for bisphosphonates in comparison with calcitonin, calcium, or raloxifene. However, these studies were not ... CIENCIASMEDICASNEWS - http://elbiruniblogspotcom.blogspot.com/ - References [ More results from CIENCIASMEDICASNEWS ] |
| 10 Nov 2009 by VeZİRH@N Raloxifene, too, has been shown to be cross-resistant to tamoxifen in Phase II trials of second-line treatment of advanced breast cancer (Buzdar et al., 1988) and appears to have equal efficacy to existing hormonal agents as first-line ... Untitled - http://www.birdunyabilgi.net/ |
| 29 Oct 2009 by Legault, Maki, Resnick, Coker, Hogan, Bevers,... The 1498 women who were randomly assigned in STAR were age 65 years and older, were not diagnosed with dementia, and were enrolled onto the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) trial, beginning 18 months after ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 14 Sep 2009 by Heidi D. Nelson, Rongwei Fu, Jessica C.... This review of 8 trials found that tamoxifen, raloxifene, and tibolone each reduced risk for invasive breast cancer in women more than placebo. Tamoxifen and raloxifene reduced risk for estrogen receptor–positive but not estrogen ... ANN INTERN MED: Most-Read Full-Text Articles - http://www.annals.org/ [ More results from ANN INTERN MED: Most-Read Full-Text Articles ] |
| 14 Nov 2009 by Randall Parker Then, in 1999, he had a chance to do another breast cancer prevention trial, this time of an osteoporosis drug, raloxifene, or Evista, which did not have the cancer drug taint. It was to be compared with tamoxifen. ... FuturePundit - http://www.futurepundit.com/ - References |
| 13 Nov 2009 by Margaret Polaneczky, MD (aka TBTAM) The maker of Evista (raloxifene) is targeting both docs and women, urging them to calculate their lifetime risk for breast cancer and consider taking the drug if that risk for breast cancer is increased. ... These symptoms can occasionally be severe, although only about 1% of users stopped the drug because of hot flashes in the clinical trials. And most women will notice an increase in vaginal mucus that, as a gynecologist, I don't have concerns about. ... The Blog that Ate Manhattan - http://theblogthatatemanhattan.blogspot.com/ - References |
| 9 Feb 2009 by Collins, P., Mosca, L., Geiger, MJ, Grady,... Raloxifene had no effect on the incidence of coronary events in any subgroup except in the case of a post hoc age subgroup analysis using age categories defined in the Women's Health Initiative randomized trials. ... Circulation recent issues - http://circ.ahajournals.org/ [ More results from Circulation recent issues ] |
| 16 Nov 2009 by David Gorski A $110 million clinical trial showed that its ability to prevent breast cancer is not statistically significantly different than that of tamoxifen, with the advantage that, unlike tamoxifen, raloxifene does not increase the risk of ... Science-Based Medicine - http://www.sciencebasedmedicine.org/ - References |
| 17 Nov 2009 by Dr. Walt Readers of my newsletters know by now that statins have serious residual risk in all their trials and only get a minority of patients to apoB or LDL Particle Count (LDL-P) goal. Per all guidelines combination therapy is indicated to achieve ... Does everyone remember that estrogen, raloxifene, Fosamax and torcetrapib all have positive CIMT data and NONE have been shown to reduce cerebrovascular disease (CVD) events? Indeed both estrogen and torcetrapib also raise HDL-C. ... Dr. Walt's Health Blog - http://www.drwalt.com/blog/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
